<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2008</study_start_year><condition>lung cancer, pharyngeal cancer, gastric cancer, jejunal cancer, ileal cancer,  pancreas cancer, biliary tract cancer,  soft tissue sarcoma</condition><disease>Lung Cancer, Pharyngeal Cancer, Gastric Cancer, Jejunal Cancer, Ileal Cancer,  Pancreas Cancer, Biliary Tract Cancer,  Soft Tissue Sarcoma</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2618328</full_dataset_link><location>Japan</location><study_start_month>12</study_start_month><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Phase II study of peptide vaccination for patients with metastatic lung or gastro-intestinal tract cancers</name><description>Interventions: peptide vaccinnation
Primary outcome(s): Evaluation of efficacy by RECIST criteria
Study Design: Single arm Non-randomized</description><dates><creation>2008-12-15</creation></dates><accession>2618328</accession><cross_references><Japan Primary Registries Network>JPRN-UMIN000002857</Japan Primary Registries Network></cross_references></HashMap>